At the core of Winn CIPP is a hands-on curriculum embedded within leading clinical research institutions across the nation. Students are strategically placed in environments where they encounter real-time challenges and best practices in clinical trial execution. This direct involvement enables them to grasp the intricacies of informed consent processes, ethical considerations, and nuanced communication strategies tailored to diverse patient populations. The program’s approach underscores the importance of synthesizing scientific inquiry with cultural competence to enhance enrollment and retention in clinical studies, addressing pervasive issues in minority and underserved communities.

The program commenced with a comprehensive virtual kickoff and program-wide learning day, gathering a robust assembly of students, academic faculty, funding sponsors, seasoned mentors, and national leaders in clinical research. This forum served not only to contextualize the historical evolution and impact of clinical trials but also to project future trajectories emphasizing innovative designs and inclusivity. Participants engaged in critical dialogues on socio-structural determinants affecting trial participation, fostering an early understanding of the multifaceted barriers to equitable clinical research.

Operating under the auspices of the Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards), the Clinical Investigator Pathway Program is a national initiative championed by Dr. Robert A. Winn himself. As the newly appointed Vice President and Director of Fox Chase Cancer Center, Dr. Winn imparts visionary leadership that transcends tradition by embedding community engagement and trust-building as central tenets of clinical investigation. His ethos drives the program’s core mission: to cultivate physician-investigators who not only excel in scientific rigor but also pioneer culturally sensitive approaches that democratize clinical trial access.

The inception of Winn CIPP in 2020 by the Bristol Myers Squibb Foundation, an independent charitable entity, signals a strategic investment in fortifying the clinical research workforce. Since its genesis, the program has attracted a collaborative constellation of funders, including major pharmaceutical players such as Gilead Sciences, Amgen, Genentech, and AstraZeneca. This financial coalition reflects a shared commitment to remedying systemic disparities by equipping emerging medical talent with the skills and perspectives requisite for advancing inclusive clinical trials.

One of the distinguishing features of this program is its focus on early-stage medical students, specifically those in their first through third years of training. This timing is critical, as it allows participants to assimilate foundational knowledge in clinical trial design, patient engagement techniques, and recruitment strategies before their clinical rotations intensify. Such early exposure primes students to critically analyze the intertwined ethical, social, and logistical considerations necessary for conducting patient-centered research, emphasizing the vital role of mitigating structural biases that hinder minority participation.

Throughout the duration of the program, students engage in a multidisciplinary educational experience, integrating mentorship, scientific inquiry, and professional development. They collaborate with dedicated mentorship teams composed of established Winn Career Development Award scholars and program alumni. This mentorship model fosters a vibrant learning community, facilitating knowledge transfer, career guidance, and networking opportunities that are pivotal for advancing careers in clinical research and healthcare innovation.

Central to the curriculum is a series of scholarly activities culminating in the generation and dissemination of original research. Each student develops abstracts, scientific posters, and delivers oral presentations, thereby honing their abilities to communicate complex scientific data effectively to diverse audiences. The program’s finale—a national symposium—provides a distinguished platform for these future physician-investigators to showcase their findings and engage in advanced discussions on clinical research methodologies and career pathways, further fostering a culture of academic excellence and inquiry.

The clinical placements for the fifth cohort encompass an impressive array of nationally recognized research hubs, including Cedars-Sinai Medical Center, City of Hope, Fred Hutchinson Cancer Center, Icahn School of Medicine at Mount Sinai, and St. Jude Children’s Research Hospital, among others. At these renowned institutions, students gain frontline experience interacting with multidisciplinary teams, patients, and community stakeholders. This exposure offers profound insights into the operational realities and ethical imperatives of conducting clinical trials within heterogeneous and often vulnerable populations.

This paradigm of mentorship and institutional partnership is integral to the program’s immersive design. Joy L. Jones, PhD, Executive Director of Winn CIPP, emphasizes that collaboration with these mentor sites provides a critical conduit for students to deeply engage with both the scientific and societal dimensions of clinical research. Such immersive experiences cultivate not only technical competencies but a nuanced appreciation for community-oriented research that is essential for improving trial participation among historically marginalized groups.

Since its establishment, Winn CIPP has initiated and supported over 321 medical students across 24 distinguished mentor institutions nationwide, thus establishing a robust national network of future leaders in clinical trial research. This expansive reach underscores the program’s success in embedding principles of equity, community engagement, and scientific integrity into the fabric of clinical research education. By fostering early recruitment and retention of diverse medical talent, Winn CIPP stands poised to significantly influence the trajectory of clinical trial participation and health outcomes across diverse populations.

Underpinning the importance of this initiative is the recognition that future advancements in medicine hinge on the ability of physician-scientists to bridge scientific innovation with empathetic, community-informed practice. By integrating technical expertise with cultural humility and patient-centric approaches, Winn CIPP cultivates a new cadre of investigators uniquely equipped to dismantle barriers and enact meaningful change in clinical trial accessibility and design. This visionary program ultimately contributes to the broader mission of achieving health equity and enhancing the predictive value and generalizability of clinical research findings for all patients.

In conclusion, the Robert A. Winn Clinical Investigator Pathway Program represents a transformative evolution in clinical research training, harnessing the power of mentorship, institutional collaboration, and early career development to shape future physician-investigators. Through its emphasis on community engagement, educational rigor, and scientific excellence, Winn CIPP not only addresses the pressing need to diversify clinical trial participation but also enriches the clinical research enterprise with culturally competent leaders poised to drive innovation and inclusion into the future of medicine.

Subject of Research: Clinical trial participation, clinical research education, community engagement in medicine

Article Title: Cultivating a Diverse and Engaged Clinical Research Workforce: The Robert A. Winn Clinical Investigator Pathway Program’s Fifth Cohort Launches

News Publication Date: June 2026

Web References: https://winnawards.org/2026/06/robert-a-winn-clinical-investigator-pathway-program-announces-cohort-5-awardees/

Keywords: Clinical trials, physician-investigators, medical education, minority participation, community engagement, clinical research workforce, health equity, mentorship programs, clinical trial access, medical students, early career scientists, health disparity, clinical trial design

Established in 2020, the Winn CDA has been instrumental in equipping physician-scientists with the necessary skills to improve clinical trial design and execution—particularly emphasizing community engagement and representation. The program’s rigorous two-year curriculum supports scholars with a $240,000 award intended to safeguard nearly half of their professional time to focus exclusively on their research and training. This structure enables fellows to develop and lead clinical trials that are methodologically robust while ensuring that participant cohorts accurately reflect the demographics affected by the diseases under study.

Historically, the Winn CDA program has concentrated its focus on areas such as oncology and cardiovascular and cardiometabolic diseases, fields where disparities in clinical trial participation have been well-documented. Expanding into neuropsychiatry represents a strategic response to the persistent challenges of participant diversity within neurological and psychiatric clinical studies. Disorders like Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and schizophrenia often disproportionately affect underrepresented communities yet remain under-investigated within those groups.

Neuropsychiatric clinical research is rapidly evolving, utilizing advanced neuroimaging, biomarker discovery, and novel neurotherapeutic approaches to unravel the complexities of brain disorders. However, clinical trials in this domain have struggled with recruitment and retention of diverse patient cohorts, limiting the generalizability and applicability of findings. Megan Becker, Executive Director of the Winn CDA program, highlighted this disparity, emphasizing the program’s commitment to fostering trials that serve all communities equitably. The inclusion of neuropsychiatry in the Winn CDA is a direct effort to bridge this gap, cultivating investigators who prioritize inclusivity and community collaboration.

Ali Gemma, Program Director of Winn CDA, stressed the importance of recruiting neuropsychiatry researchers whose work aligns with diseases that impact millions worldwide yet suffer from limited clinical trial representation. By focusing on these critical conditions, Winn CDA aims to generate pivotal data that accurately reflects patient diversity, ultimately informing tailored therapeutic interventions and improving clinical outcomes. The program envisions training physician-scientists capable of designing trials that are not only scientifically rigorous but also community-oriented and culturally sensitive.

The Winn Awards program was established by the Bristol Myers Squibb Foundation and has since attracted additional support from industry leaders such as Gilead Sciences, Amgen, and Genentech. These partnerships are essential for maintaining the program’s sustainability and expanding its reach to new research frontiers. By leveraging these collaborations, Winn Awards ensures that its scholars have access to cutting-edge resources, mentorship, and networks necessary for driving innovations in clinical trial methodologies and improving patient representation.

Applicants interested in the Winn CDA’s newly broadened eligibility are encouraged to submit their proposals by May 4, 2026. Prospective candidates can expect comprehensive support from the Winn CDA team, which offers guidance on application procedures and tailored advice to help prepare competitive submissions. This open line of communication aims to reduce barriers for physician-scientists entering the field and enhance the quality of scientific inquiry within the program.

Clinical trial inclusivity remains a critical concern within medical research, as historically marginalized populations continue to face systemic obstacles that delay or prevent their participation in studies. The Winn CDA’s expansion into neuropsychiatry reflects an acknowledgment of these complexities and positions the program as a leader in fostering equitable and impactful research practices. By emphasizing multidisciplinary training and community engagement, Winn awards are addressing underlying structural inequities that hinder scientific progress and equitable healthcare delivery.

The program’s design incorporates hands-on mentorship alongside didactic training, giving investigators practical tools to navigate regulatory pathways, community partnerships, and data management challenges inherent in clinical trial conduct. Scholars receive mentorship from leaders with expertise in trial design, patient engagement, and health disparities research. This holistic approach ensures that Fellows emerge not only as capable researchers but as advocates for the populations they serve, equipped to make paradigm-shifting contributions in neuropsychiatric research.

With neuropsychiatric disorders posing escalating healthcare burdens globally, particularly among aging and underserved populations, the Winn CDA initiative’s timing could not be more critical. As clinical trials begin incorporating novel biomarkers, digital health technologies, and adaptive trial designs in neuropsychiatry, the need for investigators trained in inclusive, representative methodologies is paramount. Winn-trained physician-scientists are positioned to lead this new era, shaping trials that translate scientific discovery into tangible patient benefits, while dismantling long-standing barriers to clinical research participation.

Ultimately, the expansion of the Winn Career Development Award to encompass neuropsychiatry signals a transformative moment in clinical research training and funding. By investing in early-career physician-scientists who commit to equity and innovation, the program advances a future where clinical trials are more inclusive, research outcomes more reliable, and therapeutic breakthroughs accessible to all patients irrespective of background. The success of this initiative promises to accelerate progress in neuropsychiatry and serve as a model for other fields striving toward comprehensive representation and impact.

Those seeking more information about eligibility and application guidelines can reach out directly to the Winn CDA team at winncda@vcu.edu. Additional program details, updates, and resources are available on the official website at www.winnawards.org. With this expansion, the Robert A. Winn Excellence in Clinical Trials Award Program renews its commitment to fostering a generation of physician-scientists equipped to conduct better science for all — delivering innovations that truly represent and benefit diverse patient communities across the neuropsychiatric disease spectrum.

Subject of Research: Expansion of clinical trial training programs to include neuropsychiatry, focusing on improving trial representativeness and inclusivity in neurological disorders.

Article Title: Robert A. Winn Excellence in Clinical Trials Award Broadens Scope to Include Neuropsychiatry Researchers

News Publication Date: March 19, 2026

Web References:

• www.winnawards.org

Image Credits: Sara Furlong

Keywords: neuropsychiatry, clinical trials, research diversity, physician-scientists, neuropsychiatric disorders, Alzheimer’s disease, Parkinson’s disease, ALS, MS, schizophrenia, clinical trial inclusivity, community engagement, Robert A. Winn Excellence in Clinical Trials Award, Winn Career Development Award